Adaptive Randomization of Neratinib in Early Breast Cancer

BACKGROUND: I-SPY2, a standing, multicenter, adaptive phase 2 neoadjuvant trial ongoing in high-risk clinical stage II/III breast cancer, is designed to evaluate multiple, novel experimental agents added to standard chemotherapy for their ability to improve the rate of pathologic complete response (...

詳細記述

保存先:
書誌詳細
出版年:N Engl J Med
主要な著者: Park, John W., Liu, Minetta C., Yee, Douglas, Yau, Christina, van 't Veer, Laura J., Symmans, W. Fraser, Paoloni, Melissa, Perlmutter, Jane, Hylton, Nola M., Hogarth, Michael, DeMichele, Angela, Buxton, Meredith B., Chien, A. Jo, Wallace, Anne M., Boughey, Judy C., Haddad, Tufia C., Chui, Stephen Y., Kemmer, Kathleen A., Kaplan, Henry G., Isaacs, Claudine, Nanda, Rita, Tripathy, Debasish, Albain, Kathy S., Edmiston, Kirsten K., Elias, Anthony D., Northfelt, Donald W., Pusztai, Lajos, Moulder, Stacy L., Lang, Julie E., Viscusi, Rebecca K., Euhus, David M., Haley, Barbara B., Khan, Qamar J., Wood, William C., Melisko, Michelle, Schwab, Richard, Lyandres, Julia, Davis, Sarah E., Hirst, Gillian L., Sanil, Ashish, Esserman, Laura J., Berry, Donald A.
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5259558/
https://ncbi.nlm.nih.gov/pubmed/27406346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1513750
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料